H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the company’s research and development day highlighted its key programs and catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Holding’s Promising Future: Advancements in Neuroprotection, Dry Eye Treatment, and Diabetic Macular Edema
- Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day
- Oculis Holding’s Promising Pipeline and Strategic FDA Alignments Support Buy Rating
- Oculis price target raised to $41 from $37 at Baird
- Oculis price target raised to $32 from $31 at BofA